The US FDA has expanded the existing indication for Celgene Corp.'s Revlimid (lenalidomide) to include its use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded indication makes Revlimid the first and only treatment to receive FDA approval for maintenance use following auto-HSCT, the company says.
Revlimid has become a foundational therapy in multiple myeloma since its first approval for this disease back in 2006 in...






